BioSante shares surge on option deal; Alkermes boasts about beefy bydureon royalties;

 @FierceBiotech: Vatican backs adult stem cell research with $2.7M. Report | Follow @FierceBiotech 

 @JohnCFierce: Contract research in China booming at a rate of 30 percent a year. Report | Follow @JohnCFierce

> Shares of BioSante surged this morning after it announced that an unnamed pharma company had inked an option deal for use of its antibody production technology. Story

> Alkermes is using its R&D day today to announce that it will reap an 8 percent royalty on the once-weekly bydureon, which is being advanced by Eli Lilly and Amylin. Report

> Aton Pharma has acquired the U.S. marketing rights to Lodosyn (carbidopa) tablets from Bristol-Myers Squibb. Aton release

And Finally... IBM scientists have created a 3D map of the earth so small that 1,000 of them could fit on one grain of salt. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.